Investors
Message to investors
Warnex is focused on providing contract laboratory services to the pharmaceutical and healthcare sectors. We are committed to quality and scientific excellence in all aspects of our business, and we have earned a reputation for providing reliable and consistent results as well as outstanding customer service. Our ultimate goal is to become a significant player in the laboratory services sector, through both acquisitions and organic growth. We have a strong track record of growth and we have acquired and successfully integrated five acquisitions in the laboratory sector.
-Mark Busgang, President & CEO
Financial Summary
| 2005 | 2006 | 2007 | 2008 | 2009 | |
|---|---|---|---|---|---|
| Revenues (‘000 $) | 18,274 | 21,098 | 25,499 | 25,787 | 23,647 |
| Employees | 192 | 291 | 288 | 256 | 259 |
| Property, plant, equip. (‘000 $) | 10,891 | 10,932 | 7,726 | 8,309 | 7,376 |
| Net earnings (‘000 $) | (4,468) | (18,205) | (1,597) | 2,373 | (164) |
| Net earnings per share ($) | (0.09) | (0.34) | (0.03) | 0.04 | 0.00 |
Latest news
- August 11, 2010
- Warnex Reports Second Quarter 2010 Results
- July 23, 2010
- India’s Investigation Bureau Seeks Warnex’s Help
- July 21, 2010
- Warnex, the Montreal Heart Institute and CEPMED Collaborate to Develop a New Diagnostic Test for Cadiovascular and Metabolic Diseases
